Complete this brief questionnaire

Check eligibility

Allergic Fungal Rhinosinusitis

Do you want to learn more and participate in a clinical trial?

What is Allergic Fungal Rhinosinusitis (AFRS)?

AFRS is a subset of Chronic Rhinosinusitis with nasal polyps (CRSwNP). Patients with AFRS experience inflammation within the nasal passage and sinuses, which is caused by an allergic reaction to fungi.

This disease is found in less than 10% of patients with CRS and is commonly found in regions with warm, humid climates.

There is no specific approved treatment for AFRS. Current treatment requires sinus surgery to remove thick mucus and nasal polyps, followed by continued treatment with corticosteroids. There is a high, early rate of recurrence after surgery which can lead to repeat surgeries, as well as the need for frequent systemic steroid use.  Therefore, there is a great need to find new therapies for control of this disease.

content image

What is the purpose of this study?

This study is to determine, if the investigational medication can:

  • Reduce the signs and symptoms in patients with AFRS.
  • Reduce the need for repeated use of oral corticosteroids and surgical intervention. 
  • Improve the overall symptom severity and quality of life in patients with AFRS.

Study Information

This study will:

  • Be conducted globally, which means, several hospitals/clinics around the world are participating.
  • Include approximately 62 patients who are at least 6 years old.
  • Have a 50% chance (one of of every two people) of receiving investigational medication or placebo.

What is the length of the study?

  • Screening Period:  Up to 4 weeks
  • Treatment Period:  Up to 52 weeks (about a year)
  • Follow-up Period:  12 weeks

The total time expected for participation is approximately one (1) year and four (4) months.

What is expected if I qualify and decide to participate?

  • You (or your child) should continue background intranasal corticosteroids spray (except nasal spray using exhalation delivery system such as Xhance™).
  • You (or your child) should continue to take the same daily dose of medication throughout the study unless experiencing a worsening of symptoms, for which rescue therapy may be initiated.        
  • If enrolled in this study, you (or your child) will receive all study-related medical care at no cost and will be seen by a doctor who will closely follow you (your child) care for AFRS.

  • Participation includes:
    • Subcutaneous (under the skin) injection of investigational medication or placebo, once every 2 weeks (or every 4 weeks if your child is ≥15 kg/33 pounds and <30 kg/66 pounds of body weight).
    • Eight hospital/clinic visits
    • Study procedures and monitoring of side effects throughout the study period

Am I (or is my child) eligible?

Terms to know:

Double Blind

Neither the patient nor the study doctor will know which treatment the patient is receiving.

Investigational medication

An investigational medication is what is being studied to see if symptoms improve while taking it. The drug is not yet approved for general use in patients with AFRS by regulatory authorities.


A placebo is an inactive substance or treatment that looks the same and is given in the way as the investigational medication that is being studied.


What is a clinical research study?

Clinical research studies are used to show if/how an investigational medication works and to find out if it is safe. They can also be referred to as clinical trials.

Clinical studies are run by qualified healthcare professionals. The doctors and other healthcare providers are responsible for the study-related care of the people that participate (or enroll) in these studies. Clinical trials are a mandatory part of the process that leads to an approval, which is required before a drug can be marketed.

Independent committees (called Institutional Review Boards or IRBs) are made up of medical and non-medical people, who also watch over clinical research studies, to make sure that the people who enroll are properly and adequately informed and consent prior to study participation.

Why are clinical trials conducted?

Clinical trials are essential to the development of new interventions (drugs, vaccines, procedures, devices) that help people to live longer and with less pain or disability.

They help researchers to understand what does and doesn’t work in humans that cannot be learned in the laboratory or in animals. Clinical trials also help doctors decide if the side effects of an investigational treatment are acceptable when weighed against the potential benefits.

How do clinical trials work?

Clinical trials must adhere to Good Clinical Practices (GCP), rigid standards that clearly state what is allowed by medical professionals during a clinical trial.

Clinical trials follow rigid testing procedures designed to help researchers determine the safety and effectiveness of the investigational drug or medical treatment being studied.

Why should I join a clinical research study?

Thousands of people volunteer to participate in clinical trials every year. The reasons for participation vary, but all of them help to advance medicine. Some reasons include:

  • Medical supervision. Some people have a disease for which there is no approved treatment. They might join a clinical trial in the hopes of receiving an investigational medicine.
  • Contribute to future treatments. Many participants wish to help future patients. This has been reported by both patients and healthy volunteers.
  • Help improve the lives of others. Some people participate with the hope of helping others. The investigational drug or vaccine could benefit other patients and, in some cases, save lives.

Who can participate in a study?

Every clinical trial has a set of criteria that study participants must meet in order to participate, including agreeing to sign an informed consent form and HIPAA authorization.

What is an informed consent?

Before deciding to participate in a clinical study, potential participants will go through a process called "informed consent". This is designed to help the participant learn more about the clinical trial before deciding whether or not to participate. 

Potential participants are given detailed information about the study. This includes the purpose, possible risks, potential benefits, how long it will take, what procedures are required and whom to contact with any questions or issues. 

Once potential participants have no further questions, the document is signed indicating the decision to participate.  An informed consent is designed to protect the study participant. It is not a contract.  A participant can ask questions or stop participating without any reason and at any time, even before the study is over.

What is a Phase III (Phase 3) trial?

Researchers compare the investigational medication with the current standard treatment or placebo. They monitor any side effects very closely. Larger groups of patients (typically several hundred to thousands of people) participate in Phase 3 clinical trials. These studies can take many years to complete and are often completed in many different locations.

The purpose of a Phase 3 trial is to determine whether the investigational medication is safe and if it has a therapeutic (beneficial) effect.

In most cases, a study participant and study doctor will not know whether they have received the investigational medication, an existing treatment, or placebo. This helps minimize any bias.

What type of study-related medical care is provided during the study?

All study-related medical care related to the study is provided, including study-related exams, study-related medications and other study-related medical care. There is no insurance required to participate. All study-related medical care will be explained.

Studies may also offer compensation in return for travel.

Is it safe to participate in a clinical trial?

All clinical trials have possible risks, some of which are known before the study starts. Before deciding to participate, the study risks will be explained. Study participants are closely monitored during the study.

While side effects may occur with any investigational medication being studied, the safety and well-being of study participants are top priorities for the sponsors, doctors, nurses and research professionals who conduct clinical trials.

Study participants can decide at any point to end participation.

What about clinical trials participation during COVID-19?

This study requires in-person visits to the study site. Precautions are being taken to reduce the on-site risks of exposure to COVID-19. Each individual site location will review their protocols including mask wearing, social distance, pre-appointment check in. Study sites are medical facilities where COVID safety procedures are followed.

The COVID-19 vaccine can be administered before entering in the study or afterwards, without needing study drug interruption. This should be discussed with your study doctor.

In order to ensure treatment continuity and safety of patients participating in our clinical trials during this worldwide pandemic, several alternative solutions have been put in place and can be accessed if they are available in your area:

  • Investigational study drug can be sent directly to you at home, to ensure that you will receive the investigational study drug even if you are unable to come to the research center/hospital/clinic
  • Telehealth/video consultation can be organized instead of on-site visits
  • Some study visits can be performed at home (home nursing)
  • The possibility to sign your consent either on paper or electronically (eConsent)

Can I speak with someone if I have questions?

Yes, after you complete the online questionnaire and give permission to be contacted, a study representative will contact with you. You can ask questions at any time, before deciding to participate and during study conduct.

I speak Spanish, not English. Can I participate in the study?

Yes, if you let the doctor know, the study site can provide you with translated materials and may be able to provide an interpreter.

V2.0, 04May2024

Photos: imagepointfr (Lydie Salaun)